<DOC>
	<DOC>NCT01216332</DOC>
	<brief_summary>This is a phase I safety and immunogenicity trial comparing high-dose (HD)trivalent inactivated influenza vaccine (TIV) to standard dose (SD) TIV in pediatric patients with Acute Lymphoblastic Leukemia.</brief_summary>
	<brief_title>Standard Versus High-Dose Trivalent Inactivated Flu Vaccine in Pediatric Acute Lymphoblastic Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Pediatric patients with standard or high risk Acute Lymphoblastic Leukemia. Must be in 1st complete remission. Must be 4 weeks into maintenance therapy. 17 years of age, inclusive. Available for duration of study. History of hypersensitivity to previous influenza vaccination or hypersensitivity to eggs/egg protein. History of GuillainBarre syndrome. Evidence of relapsed disease. Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol. Have any condition that the investigator believes may interfere with successful completion of the study. History of receiving 2010 2011 influenza vaccine. Pregnant female. History of proven influenza disease after September 1, 2010.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>